Why the study?
What is the natural history and 5-year survival rate of central-type osteogenic sarcoma in the long bones of patients under 21 years of age?
What is the natural history and 5-year survival rate of central-type osteogenic sarcoma in the long bones of patients under 21 years of age?
The 5-year survival rate for osteogenic sarcoma in patients under 21 was 17.4%, providing a historical control series for evaluating future treatments.
Answers are grounded in this paper and cite their sources.
Provides a historical control benchmark for central osteogenic sarcoma in adolescents; leaves open the impact of modern therapies.
A consecutive series of 145 central-type osteogenic sarcomas in the long bones of patients under the age of twenty-one years was studied by analysis of the interval from surgery to onset of pulmonary metastasis and the interval from the onset of pulmonary metastasis to death. The effects of the time of surgery, age, sex, race, preoperative duration of symptoms, location of tumor, and preoperative radiation on the course of the disease were analyzed. One hundred and twenty-one patients had pulmonary metastasis prior to the end of the study and died of their disease. Twenty-four patients were free of metastasis at the end of the study. The five-year survival rate was 17.4 per cent. Age and location of the tumor were found to affect the time of onset of pulmonary metastasis but not the five-year survival figure. The first two years after definitive surgery were shown to be the critical period for studying the course of the disease. The data analyzed in this study may offer a valuable control series against which future methods of treatment can be evaluated.
No takes yet. Share an insight, caveat, or question.
Marcove et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: